Share Price:

APNASPENAspen Pharmacare Hldgs19002112 (0.59%)

Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported a strong performance for the year ended 30 June 2023. SALIENT HIGHLIGHTS Revenue grew by 5% (-3% in constant exchange rate (“CER”)) to R40 709 million (FY2022: R38 606) Normalised EBITDA rose by 1% (-6% in CER) to R11… Continue reading Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated

FY2023 Sustainability and ESG Data Supplement

View or Download

2023 Capital Markets Day Presentation

View or Download

2023 Capital Markets Day Webcast

View the webcast playback

Aspen reports a creditable and resilient performance under challenging trading conditions

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported creditable unaudited interim Group financial results for the six months ended 31 December 2022.   Salient Highlights   Revenue decreased by 1% (-6% in constant exchange rate (“CER”)) to R19,2 billion (December 2021: R19,4 billion) Normalised EBITDA decreased by… Continue reading Aspen reports a creditable and resilient performance under challenging trading conditions

FY2023 Integrated Report

View the online version and select download options

Tragic passing of Riaan Verster (46)

Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), regrets to announce the untimely and tragic passing of Riaan Verster, Aspen Group Executive: Governance & Communications, on Saturday 28 January 2023. Riaan regrettably succumbed to his injuries sustained in a motor cycle accident.   Stephen Saad, Aspen Group Chief Executive, said, “Riaan was a dear… Continue reading Tragic passing of Riaan Verster (46)

Aspen, CEPI and the Bill & Melinda Gates Foundation expand commitments to improve access to vaccines in Africa

Stephen Saad, Aspen Group Chief Executive

New funding supports technology transfer from Serum Institute to Aspen to manufacture routine vaccines in Africa, for Africa Collaboration supports sustainable manufacturing capacity for African-produced vaccines for future epidemics and pandemics   Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”) a global multinational specialty pharmaceutical company,  announced that it will receive USD30 million… Continue reading Aspen, CEPI and the Bill & Melinda Gates Foundation expand commitments to improve access to vaccines in Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.